Published in Nature on August 12, 2012
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
Revisiting global gene expression analysis. Cell (2012) 3.63
The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood (2016) 3.21
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell (2012) 3.10
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med (2015) 2.42
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet (2014) 2.34
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med (2013) 2.31
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07
MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J (2013) 2.01
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood (2013) 1.84
CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood (2012) 1.79
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell (2015) 1.76
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med (2014) 1.70
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol (2013) 1.66
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet (2015) 1.52
DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma. J Exp Med (2015) 1.48
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 1.44
Salvador-Warts-Hippo pathway in a developmental checkpoint monitoring helix-loop-helix proteins. Dev Cell (2015) 1.42
UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma. Blood (2015) 1.39
B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol (2013) 1.39
Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood (2012) 1.38
MYC, Metabolism, and Cancer. Cancer Discov (2015) 1.29
DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. Nat Genet (2015) 1.26
Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica (2016) 1.23
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet (2015) 1.23
Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature (2014) 1.23
RNA CoMPASS: a dual approach for pathogen and host transcriptome analysis of RNA-seq datasets. PLoS One (2014) 1.14
Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med (2014) 1.12
The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood (2014) 1.08
B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol (2015) 1.08
Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica (2013) 1.05
Systematically differentiating functions for alternatively spliced isoforms through integrating RNA-seq data. PLoS Comput Biol (2013) 1.04
MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase. Cancer Res (2012) 1.04
Sample processing obscures cancer-specific alterations in leukemic transcriptomes. Proc Natl Acad Sci U S A (2014) 1.04
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Front Oncol (2014) 1.03
Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer (2014) 1.02
A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood (2014) 0.98
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle (2013) 0.98
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol (2014) 0.97
E and Id proteins influence invariant NKT cell sublineage differentiation and proliferation. J Immunol (2014) 0.97
A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. Nat Commun (2014) 0.97
Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood (2013) 0.96
A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells. J Clin Invest (2013) 0.96
The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood (2013) 0.96
Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood (2014) 0.95
Building capacity for sustainable research programmes for cancer in Africa. Nat Rev Clin Oncol (2014) 0.94
Targeting the Checkpoint to Kill Cancer Cells. Biomolecules (2015) 0.94
Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. Blood Cancer J (2013) 0.94
Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J (2013) 0.94
Stages versus subsets: Invariant Natural Killer T cell lineage differentiation. Cytokine (2015) 0.92
Burkitt Lymphoma: beyond discoveries. Infect Agent Cancer (2013) 0.91
Evolving understanding of the CLL genome. Semin Hematol (2014) 0.91
Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature. J Virol (2012) 0.89
ID'ing innate and innate-like lymphoid cells. Immunol Rev (2014) 0.89
Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma. Leukemia (2013) 0.88
HLA typing from RNA-seq data using hierarchical read weighting [corrected]. PLoS One (2013) 0.88
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. J Clin Oncol (2015) 0.88
Base-pair resolution DNA methylome of the EBV-positive Endemic Burkitt lymphoma cell line DAUDI determined by SOLiD bisulfite-sequencing. Leukemia (2013) 0.88
The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia (2015) 0.88
EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med (2015) 0.87
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet (2015) 0.87
The tumor virus landscape of AIDS-related lymphomas. Blood (2015) 0.87
Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications. Cancers (Basel) (2015) 0.86
Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget (2015) 0.86
A common functional consequence of tumor-derived mutations within c-MYC. Oncogene (2014) 0.86
Burkitt lymphoma risk in U.S. solid organ transplant recipients. Am J Hematol (2013) 0.86
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma. PLoS Pathog (2015) 0.86
Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood (2015) 0.86
Pathology of lymphoma in HIV. Curr Opin Oncol (2013) 0.86
The E-Id protein axis modulates the activities of the PI3K-AKT-mTORC1-Hif1a and c-myc/p19Arf pathways to suppress innate variant TFH cell development, thymocyte expansion, and lymphomagenesis. Genes Dev (2015) 0.85
Lymphocyte lineage-specific and developmental stage specific mechanisms suppress cyclin D3 expression in response to DNA double strand breaks. Cell Cycle (2016) 0.85
The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer Discov (2017) 0.84
The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential. Oncotarget (2015) 0.84
Potential cellular functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus. Viruses (2013) 0.84
Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma. Proc Natl Acad Sci U S A (2014) 0.84
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. Mol Oncol (2013) 0.84
ID helix-loop-helix proteins as determinants of cell survival in B-cell chronic lymphocytic leukemia cells in vitro. Mol Cancer (2015) 0.84
Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res (2014) 0.84
D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. Nat Commun (2015) 0.83
The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia (2015) 0.83
Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol (2014) 0.83
Epstein-Barr virus patterns in US Burkitt lymphoma tumors from the SEER residual tissue repository during 1979-2009. APMIS (2013) 0.83
ID proteins regulate diverse aspects of cancer progression and provide novel therapeutic opportunities. Mol Ther (2014) 0.82
SUMOylation of Myc-family proteins. PLoS One (2014) 0.82
Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival. Proc Natl Acad Sci U S A (2016) 0.81
Autoinhibitory Interdomain Interactions and Subfamily-specific Extensions Redefine the Catalytic Core of the Human DEAD-box Protein DDX3. J Biol Chem (2015) 0.81
E Proteins and ID Proteins: Helix-Loop-Helix Partners in Development and Disease. Dev Cell (2015) 0.81
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene (2015) 0.81
Burkitt lymphoma with initial clinical presentation due to infiltration of the central nervous system and eye orbits. Am J Case Rep (2014) 0.80
Synergy of Myc, cell cycle regulators and the Akt pathway in the development of aggressive B-cell lymphoma in a mouse model. Leukemia (2014) 0.80
B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica (2014) 0.80
Monoubiquitination and activity of the paracaspase MALT1 requires glutamate 549 in the dimerization interface. PLoS One (2013) 0.80
Transfection of microRNA Mimics Should Be Used with Caution. Front Genet (2015) 0.80
MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget (2015) 0.80
Phosphoinositide 3-kinase inhibitors in lymphoma. Curr Opin Oncol (2014) 0.80
The Crebbp Acetyltransferase is a Haploinsufficient Tumor Suppressor in B Cell Lymphoma. Cancer Discov (2017) 0.80
Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. Oncoimmunology (2016) 0.79
Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance. Oncotarget (2015) 0.79
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell (1989) 21.54
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell (1989) 14.24
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev (1998) 12.55
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1982) 11.15
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A (1982) 10.50
Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 10.42
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell (1997) 7.18
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res (2005) 4.84
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol (2011) 4.77
PI3 kinase signals BCR-dependent mature B cell survival. Cell (2009) 4.43
A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate. Nat Immunol (2010) 4.32
Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell (2004) 4.31
Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer (2006) 3.72
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1991) 3.69
Cellular myc oncogene is altered by chromosome translocation to an immunoglobulin locus in murine plasmacytomas and is rearranged similarly in human Burkitt lymphomas. Proc Natl Acad Sci U S A (1983) 3.40
Crystal structure of transcription factor E47: E-box recognition by a basic region helix-loop-helix dimer. Genes Dev (1994) 3.30
E and ID proteins branch out. Nat Rev Immunol (2009) 2.68
Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity (1998) 2.42
Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity (2008) 2.11
Biology and treatment of Burkitt's lymphoma. Curr Opin Hematol (2007) 1.45
Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood (2011) 1.40
Distinct roles for E12 and E47 in B cell specification and the sequential rearrangement of immunoglobulin light chain loci. J Exp Med (2009) 1.34
The loop region of the helix-loop-helix protein Id1 is critical for its dominant negative activity. Mol Cell Biol (1993) 1.30
Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. Mol Cell Biol (2010) 1.24
Requirement for cyclin D3 in germinal center formation and function. Cell Res (2010) 1.16
Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. Br J Haematol (2011) 1.12
P38SAPK2 phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation. Oncogene (2004) 1.09
Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes. J Exp Med (1997) 1.08
Current investigations and treatment of Burkitt's lymphoma in Africa. Trop Doct (2008) 0.93
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
International network of cancer genome projects. Nature (2010) 20.35
Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 16.74
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Empirical studies assessing the quality of health information for consumers on the world wide web: a systematic review. JAMA (2002) 13.61
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res (2010) 10.97
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Epstein-Barr virus: 40 years on. Nat Rev Cancer (2004) 9.70
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
De novo transcriptome assembly with ABySS. Bioinformatics (2009) 8.38